Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplastic Processes × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 87 Carcinoma, Renal Cell 63 Neoplasm Metastasis 38 Neoplasms 32 Neuroendocrine Tumors 31 Kidney Neoplasms 24 Recurrence 16 Carcinoma, Non-Small-Cell Lung 16 Tuberous Sclerosis 14 Prostatic Neoplasms 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 12 Glioblastoma 12 Carcinoma, Hepatocellular 12 Pancreatic Neoplasms 11 Lymphoma, Mantle-Cell 11 Lymphoma 11 Brain Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Hodgkin Disease 10 Colorectal Neoplasms 10 Carcinoma, Neuroendocrine 10 Sarcoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Glioma 9 Waldenstrom Macroglobulinemia 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoid Tumor 8

Interventions

pembrolizumab 2 Pemetrexed 2 nilotinib 1 glutathione pegylated liposomal doxorubicin 1 ficlatuzumab 1 Zoledronic Acid 1 Trastuzumab 1 Radiosurgery 1 MRX-2843 1 Everolimus 1 Electrochemotherapy 1 Denosumab 1 Cisplatin 1 Carboplatin 1 Bleomycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01178151 2015-04-22

EVAMP

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Withdrawn

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Peutz-Jeghers Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡